Back to School: How biopharma can reboot drug development. Access exclusive analysis here

CRL buying IRGI for $1.5 billion

Preclinical services company Charles River (CRL) will acquire CRO Inveresk Research Group (IRGI) in a stock and cash deal worth $1.5 billion based on CRL's June 30 closing price

Read the full 292 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE